LONDON: Diurnal Group plc announced the launch of Efmody (hydrocortisone modified-release hard capsules) in Germany and Austria as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH), following approval by the European Commission in May 2021.
Following the launch of Alkindi (hydrocortisone granules in capsules for opening) in Germany in 2018, Efmody is now the second product that Diurnal has brought to market in Europe. Efmody pricing has been published today in the LAUER-TAXE (the reference for all German pharmacies, insurers and wholesalers) and is in line with the Company’s expectations.
In addition, the pricing for Efmody in Austria has also been published in the Warenverzeichnis (the reference for all Austrian pharmacies, insurers and wholesalers) managed by the Apotheker-Verlages.
As part of the pan-European commercialisation programme for Efmody, Diurnal is currently in discussions with various health authorities across the European Economic Area to ensure timely launches in other major European countries.
As previously announced, the Company intends to mirror its strategy for Alkindi by commercialising the product itself in core European markets given the concentrated prescribing base, relationships already established from Alkindi, and to retain the full value of the product.
Efmody is a preparation of hydrocortisone that has been specifically designed for patients with CAH, a rare condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect a total of approximately 36,000 people in the European Economic Area.
Martin Whitaker, Chief Executive Officer of Diurnal, commented: “With the launch of Efmody in Germany and Austria, Diurnal has achieved a significant milestone through the commercialisation of our second product. Importantly, the launch of Efmody alongside our first product Alkindi, means that patients in Europe with CAH will now have the option of lifelong treatment with products specifically designed for their disease. We look forward to expanding our reach within Europe in the coming months and helping to provide treatment to these patients where there is a significant unmet need.”
Diurnal Group PLC share price
58.00 GBX+0.50 (0.87%)today
1 Sep, 8:43 am GMT+1 ·Disclaimer
Leave a Reply